General Overview
- Wet AMD and DME: Driven by VEGF-mediated choroidal neovascularization (wet AMD) and vascular permeability/angiogenesis (DME).
- Traditional anti-VEGF therapy: Gold standard (e.g., ranibizumab, aflibercept 2 mg), but requires frequent injections (q4–8 weeks), leading to treatment burden and reduced real-world BCVA vs. trials.
- Faricimab (approved 2022): Bispecific antibody targeting VEGF-A and angiopoietin-2.
- High-dose aflibercept (8 mg, approved 2023): Higher concentration of standard aflibercept, targets VEGF only.
- Goal: Extend dosing intervals while maintaining efficacy.
Faricimab Clinical Trials
- Wet AMD:
- AVENUE (Phase II): Faricimab vs. ranibizumab; no BCVA increase at 36 weeks but suggested durability.
- STAIRWAY: q12w or q16w faricimab comparable to q4w ranibizumab in BCVA and anatomy.
- TENAYA/LUCERNE (Phase III): q16w faricimab noninferior to q8w aflibercept in treatment-naïve patients; >70% achieved ≥q12w dosing by week 112 (2 years).
- Meta-analysis (Yen et al.): Comparable BCVA, superior CNV/CST reduction, no difference in adverse events.
- DME:
- BOULEVARD (Phase II): Faricimab superior to ranibizumab in BCVA, CST, DRSS, with durability.
- YOSEMITE/RHINE (Phase III): q16w faricimab noninferior to q8w aflibercept; 60% achieved q16w by week 92 (2 years); greater CST reduction.
- SWAN (ongoing): q8–24w treat-and-extend in Japan.
- Meta-analysis (Li et al.): No BCVA/adverse event differences; CST improved in DME, not wet AMD.
Faricimab Real-World Studies
- Wet AMD:
- Treatment-naïve: Consistent anatomic improvements (CST reduction); BCVA gains 59–62 ETDRS letters (Quah et al.).
- Treatment-resistant: Improved anatomy after switching (CST reduction); BCVA variable; intervals extended (e.g., 5.9 to 7.6 weeks, Ambati et al.).
- Khanani et al. (376 eyes): BCVA/CST gains in resistant eyes, less significant in naïve eyes.
- DME:
- TAHOE: Anatomic and BCVA improvements.
- Treatment-naïve: 61–73 ETDRS letters (Quah et al.).
- Switching from aflibercept: Improved BCVA/CFT (Rush et al.); anatomic gains common, BCVA variable; intervals extended (e.g., +1.4 weeks, Borchert et al.).
- Exception: Kusuhara et al. reported no gains (low injection frequency, 1.6 average).
High-Dose Aflibercept Clinical Trials
- Wet AMD:
- CANDELA (Phase II): 8 mg vs. 2 mg aflibercept; no primary endpoint met at 16 weeks, but trends toward better BCVA/anatomy by 44 weeks.
- PULSAR (Phase III): q12w/q16w 8 mg noninferior to q8w 2 mg aflibercept in BCVA at 48 weeks; similar safety profile.
- DME:
- PHOTON (Phase II/III): q12w/q16w 8 mg noninferior to q8w 2 mg aflibercept in BCVA at 48 weeks; 89% maintained >q12w dosing at 96 weeks.
- Safety (Schneider et al.): 8 mg comparable to 2 mg across trials.
High-Dose Aflibercept Real-World Studies
- Limited data; real-world outcomes pending due to recent approval (August 2023).
- Need for studies to account for demographics, compliance, and prior treatment effects.
Clinical Implications
- Extended durability: Faricimab (up to q16w) and high-dose aflibercept (up to q16w) reduce injection frequency vs. standard q4–8w anti-VEGF.
- Faricimab: Robust trial and real-world evidence; anatomic gains consistent, BCVA variable.
- High-dose aflibercept: Strong trial data, real-world validation lacking.
- Challenges: Higher cost, insurance step therapy (requiring cheaper agents first), switch vs. naïve patient responses.
- Systemic impact: Reduced treatment burden could ease demand on retina specialists.
Key Takeaways
- Faricimab and high-dose aflibercept are noninferior to standard anti-VEGF with longer dosing intervals.
- Research gaps: Comprehensive real-world data for high-dose aflibercept; longitudinal outcomes for both agents across diverse populations.